Compulsory Vaccination Against Terrorist Attack Is Unjustified, Author Says

Article

The compulsory use of vaccines to prevent the effects of a bioterrorist attack seems to be based on an unproved threat, according to an editorial in this week's British Medical Journal.

 

In 1997 the United States began a compulsory anthrax vaccination program for military personnel. In 2002, a similar program also involving civilians, was started against smallpox. Yet these programs rely on old vaccines for which relatively few data exist, writes Tom Jefferson.

 

For instance, no large scale trial of the US anthrax vaccine (AVA) has ever been conducted, and trials of the current smallpox vaccine have recently been halted because of safety concerns. Despite this, the website of the United States anthrax vaccine immunization program claims proved protection against inhalation anthrax, says the author. Newer vaccines are currently being developed but are a long way from field testing.

 

"Although field trials are expensive and complex, investment in evaluation and in better and safer vaccines surely must be a requisite to have credible compulsory immunization programs involving huge numbers of adults of reproductive age," adds the author. "Until such time, the choice of whether to be vaccinated or not should be left to the individual."

 

To view the full editorial, go to:

http://press.psprings.co.uk/bmj/september/edit524.pdf

 

Reference: BMJ 4 September 2004 edition. Editorial: Bioterrorism and compulsory vaccination BMJ Volume 329, pp 524-5.

 

Source: British Medical Journal

 

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
COVID-19 infection (Adobe Stock327378972 by rost9)
Swarm of Mosquitoes on Green Background Disease Carriers Insect Infestation  (Adobe Stock 1609688034 by Amith)
Structural detail of Hepatitis B virus on blue-green background. 3D illustration (Adobe Stock 239268660 by Destina)
© 2025 MJH Life Sciences

All rights reserved.